Abstract | BACKGROUND: METHODS: MTT assay, confocal laser scanning microscope, and H&E staining were utilized to establish the efficacy and safety of CU/FU-LN. RESULTS: The AUC(0-t) of CU/FU-LN was 8.85-fold and 8.59-fold greater than those of CU and FU, respectively. The IC50 of CU/FU-LN was 4.6-fold and 4.9-fold lower than those of FU and CU in HepG2 cells, respectively. In vivo anti- tumor trials, the tumor inhibition rate was significantly elevated by CU/FU-LN (49.29%), compared 24.84% and 4.72% for FU and CU, respectively. Ki-67 immunohistochemical analysis revealed that CU/FU-LN had an obvious anti-proliferation effect. The IC50 of CU/FU-LN in L02 cells was 1.51-fold and 2.60-fold higher than those of CU and FU, respectively. Certain vital organs in the mice of the CU/FU-LN group showed markedly fewer lesions than those of the CU, FU, and CU+FU groups. The CU/FU-LN treatment caused no significant change in mouse body weight relative to the control group (P > 0.05). CONCLUSIONS: We successfully prepared a promising co-delivery platform for the synergistic treatment of liver cancer and it has a comparatively enhanced efficacy and mitigated toxicity.
|
Authors | Pu Guo, Chao Pi, Shijie Zhao, Shaozhi Fu, Hongru Yang, Xiaoli Zheng, Xiaomei Zhang, Ling Zhao, Yumeng Wei |
Journal | Expert opinion on drug delivery
(Expert Opin Drug Deliv)
Vol. 17
Issue 10
Pg. 1473-1484
(10 2020)
ISSN: 1744-7593 [Electronic] England |
PMID | 32749895
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Cell Line, Tumor
- Cell Proliferation
(drug effects)
- Curcumin
(administration & dosage, pharmacology)
- Fluorouracil
(administration & dosage)
- Hep G2 Cells
- Humans
- Liver Neoplasms
(drug therapy)
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Rats
- Rats, Sprague-Dawley
|